Shaohua H. Ge

Tianjin Key Laboratory Of Digestive Cancer, Huan Huxi Road
Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2.

Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2.

Journal: Journal of gastroenterology

Published: November 24, 2025

Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy.

Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy.

Journal: Journal for immunotherapy of cancer

Published: November 05, 2024

Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer.

Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer.

Journal: Investigational new drugs

Published: October 21, 2024

The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center.

The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center.

Journal: BMC cancer

Published: September 07, 2024

Effect of comorbidity classes on survival of patients with gastrointestinal tract cancer.

Effect of comorbidity classes on survival of patients with gastrointestinal tract cancer.

Journal: BMC cancer

Published: July 15, 2024

Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial.

Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial.

Journal: Nature communications

Published: June 30, 2024

Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study.

Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study.

Journal: Cancer immunology, immunotherapy : CII

Published: April 21, 2024

The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study

The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: November 15, 2023

Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma.

Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma.

Journal: BMC cancer

Published: August 26, 2023

Retraction Note: Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7.

Retraction Note: Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7.

Journal: Oncogene

Published: July 24, 2023

Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study.

Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study.

Journal: BMC cancer

Published: July 15, 2023

The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer.

The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer.

Journal: BMC cancer

Published: March 06, 2023

Showing 1-12 of 50

Last Updated: 09/26/2026